Attention AACR Annual Meeting 2018 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Advances in Precision Cancer Medicine

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors
Vivek Subbiah
Department of Investigational Cancer Therapeutics The University of MD Anderson Cancer Texas, Houston, TX, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Discussant
Alexander E Drilon
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
Alice T. Shaw
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Discussant
Christine M. Lovly
Vanderbilt Univ. School of Medicine, Nashville, TN, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE"
Patrick Schoffski
Catholic Univ. of Leuven - Leuven Cancer Inst., Leuven, Belgium
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Discussant
Benjamin J Solomon
Peter MacCallum Cancer Ctr., Melbourne, Australia
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
Komal Jhaveri
Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Discussant
Timothy A Yap
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8